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OBJECTIVE: To describe responses of cats prescribed a hydrolysed diet with or without concurrent 
 medication for chronic vomiting and/or diarrhoea of undetermined aetiology.
MATERIALS AND METHODS: Anonymised records of 512,213 cats under UK veterinary care in 2016 from the 
VetCompass database were searched using relevant terms for hydrolysed diets. The records of 5000 
(90%) of 5569 cats with evidence of receiving a hydrolysed diet were randomly reviewed for gastroin-
testinal indication, prior and concurrent medication and response after hydrolysed dietary intervention. 
A poor response was defined as evidence of receiving antibiotic or glucocorticoid treatment for vomit-
ing/diarrhoea at visits after the onset of the diet or death from gastrointestinal signs for at least 
6 months follow-up.
RESULTS: Of 977 cats prescribed a hydrolysed diet for chronic vomiting/diarrhoea, 697 (71%) were first 
prescribed the diet without concurrent antibiotics or glucocorticoids while 280 (29%) first received 
the diet with these medications. Thirty-four per cent of cats in the former group and 61% in the latter 
had a poor response. Cats older than 6 years and cats prescribed antibiotic and/or glucocorticoid for 
vomiting/diarrhoea before and concurrently with the diet had higher odds of poor response.
CLINICAL SIGNIFICANCE: Although variations in our observations may reflect severity of signs or prescribing 
habits of primary-care veterinary surgeons, our study suggests there is merit in trialling a hydrolysed 
diet first as a sole therapy in cats with chronic vomiting/diarrhoea when diagnostic investigations do 
not reveal a cause, before resorting to antibiotic and/or glucocorticoid therapy for cases that 
respond poorly.
INTRODUCTION
Feline chronic enteropathy (CE) describes a spectrum of diseases 
resulting in chronic gastrointestinal (GI) signs, with unknown 
aetiology (Willard 1999). However, the pathogenesis is hypoth-
esised to involve the variable interplay of four key components; 
genetic susceptibility, environmental risk factors, intestinal dys-
biosis and altered GI mucosal immune response (Jergens 2012). 
Definitive diagnosis of CE requires ruling out all known causes 
of chronic GI signs with extensive laboratory and faecal testing, 
trans-abdominal ultrasound and GI histopathology. Treatment 
often requires a sequential or combination approach with diet, 
antibiotics and immunosuppressive medication depending on 
the severity of the disease (Jergens 2012). However, the number 
of cats in primary practice that are treated empirically for CE, 
without extensive diagnostic tests, due to financial or logistical 
constraints or contraindications to general anaesthesia for collec-
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Commercial hydrolysed, limited ingredient novel protein, 
highly digestible or high fibre diets have been used for sus-
pected or confirmed feline CE (Nelson et al.  1984, Dennis 
et al. 1992, 1993, Hart et al. 1993, Guilford et al. 2001, Man-
digers et al.  2010a, Laflamme et al.  2012, Perea et al.  2017). 
Although, only one small published study specifically evalu-
ated the response to hydrolysed diets in cats with CE (Mandi-
gers et al.  2010a), it is suspected that this category of diets is 
frequently used in suspected or confirmed cases of CE in cats 
in primary practice. Unfortunately, no information is currently 
available with regards to the use of hydrolysed diet for chronic 
GI signs of undetermined aetiology in cats in primary practice. 
Therefore, it is unknown how many cats that are empirically 
treated with a hydrolysed diet with or without concurrent medi-
cation for chronic vomiting and/or diarrhoea in primary practice 
subsequently return with on-going GI signs requiring treatment 
with antibiotic and/or glucocorticoid or are euthanased due to 
these signs. These results could assist veterinary practitioners and 
owners to build an evidence base for the application of hydro-
lysed diets within clinical management protocols for chronic GI 
signs in cats in the general population. These results will also 
help to provide a benchmark for the use of, and response to, 
hydrolysed diets in primary practice for chronic vomiting and/or 
diarrhoea in cats to allow for comparisons to future similar stud-
ies utilising alternative diets.
Therefore, using anonymised veterinary clinical data from the 
VetCompass™ Programme (VetCompass 2019), our study aimed 
to describe responses of cats prescribed a hydrolysed diet with or 
without concurrent antibiotic and/or glucocorticoid for chronic 
vomiting and/or diarrhoea of undetermined aetiology. A second 
aim was to determine if antibiotic or glucocorticoid use for vom-
iting and/or diarrhoea before or concurrently with the hydro-
lysed diet was associated with response.
METHODS
Study outcomes
The primary outcome of our study was to describe responses of 
cats prescribed a hydrolysed diet with or without concurrent anti-
biotic and/or glucocorticoid for chronic vomiting and/or diar-
rhoea of undetermined aetiology. A secondary outcome was to 
determine if antibiotic or glucocorticoid use for vomiting and/
or diarrhoea before or concurrently with the hydrolysed diet was 
associated with response. The study population included all cats 
under primary veterinary care at clinics participating in the Vet-
Compass Programme during 2016. Cats under veterinary care 
were defined as those with either (1) at least one electronic patient 
record (EPR) (VeNom diagnosis term, free-text clinical note, 
treatment or bodyweight) recorded during 2016 or (2) at least one 
EPR recorded during both 2015 and 2017. VetCompass collates 
de-identified EPR data from primary-care veterinary practices in 
the UK for epidemiological research (VetCompass 2019). Data 
fields available to VetCompass researchers include a unique ani-
mal identifier along with species, breed, date of birth, colour, sex 
and neuter status, and also clinical information from  free-form 
text clinical notes, summary diagnosis terms (The VeNom Cod-
ing Group 2019) and treatment with relevant dates.
Study design
A cohort study of cats prescribed a hydrolysed diet for chronic 
vomiting and/or diarrhoea was undertaken within this VetCom-
pass population. A single operator reviewed and performed all 
data extraction from the medical records. Chronic was defined as 
evidence of at least 2 weeks of clinical signs, and was consistent 
with previous publications assessing the effects of diet in cats with 
idiopathic GI signs (Dennis et al. 1992, 1993, Hart et al. 1993, 
Guilford et al. 2001). Identification of cats that were prescribed 
a hydrolysed diet involved initial screening of all 512,213 study 
cats for candidate hydrolysed diet cases by searching the treat-
ment field using the terms zd, z/d, HA, hypoallergenic, analler-
genic and allergy (Paiva 2013). This resulted in 5569 potential or 
candidate cases. Candidate hydrolysed diet cases were randomly 
ordered by the VetCompass programme and the clinical notes of 
5000 (90%) candidate animals were reviewed in detail to evalu-
ate for case inclusion.
Inclusion criteria
Inclusion criteria were: (1) first received a hydrolysed diet for 
persistent or intermittent vomiting and /or diarrhoea of at least 
2 weeks duration, (2) there was no evidence of concurrent condi-
tions that might additionally be associated with receiving these 
therapeutic diets, e.g. dermatological disease, (3) no evidence 
that the diet was refunded or discontinued within 1 month of 
dispensing, (4) referral notes were available if cases were referred 
for their GI signs, (5) had at least 6 months follow-up at the same 
practice unless they died or were euthanased due to their GI 
signs and (6) diagnostic investigations did not reveal an aetiology 
for the chronic vomiting and/or diarrhoea, apart from chronic 
inflammatory enteropathy (Table 1).
Exclusion criteria
Additional exclusion criteria included: (1) the cat was already 
receiving a hydrolysed diet for vomiting and/or diarrhoea at the 
first available EPR and therefore prior medical records regarding 
the GI signs were not available for review and (2) glucocorticoids 
were started within 1 week of first prescribing the diet for concur-
rent non-GI condition (Table 1, Fig. 1).
Data extraction
The medical records from all cats within the 5000 candidate cases 
selected, that met the inclusion criteria and none of the exclusion 
criteria, were reviewed in detail and the following information 
was extracted for each case: (1) whether dewormer, antibiotic 
or glucocorticoid had ever been prescribed for vomiting/diar-
rhoea at any visits before the visit where the hydrolysed diet was 
first prescribed. There was no time limit to when prior visits for 
vomiting/diarrhoea were evaluated and therefore this was depen-
dent on the duration of medical records that were available for 
each case, (2) whether antibiotic or glucocorticoid was concur-
rently prescribed at the same visit as when the hydrolysed diet 
was first prescribed, (3) whether antibiotic or glucocorticoid was 
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prescribed for vomiting/diarrhoea at a subsequent visit after the 
hydrolysed diet was first prescribed for a minimum follow-up 
period of 6 months. For those cases that received the diet with 
concurrent glucocorticoids, whether this medication was tapered 
and discontinued within the 3-month period after initiation of 
the diet was also extracted. Further information included (4) 
whether non-glucocorticoid anti-inflammatory or immunosup-
pressive medication was prescribed at subsequent visits for vom-
iting/diarrhoea after the hydrolysed diet was first prescribed and 
(5) whether the cat died or was euthanased for signs associated 
with their GI disease (Table 1).
Definition of poor response
A poor response was defined as evidence in the records of the 
cat receiving intervention with antibiotic or glucocorticoid for 
vomiting/diarrhoea at a subsequent visit after the diet was first 
prescribed or death was reported associated with the GI signs 
within the follow-up period of a minimum of 6 months. For those 
cases that received the diet with concurrent glucocorticoid, a poor 
response was defined as receiving intervention with further glu-
cocorticoid or antibiotic for vomiting/diarrhoea at least 3 months 
after the diet was first prescribed or death from GI signs (Table 2).
Statistical analysis
Data were checked for internal validity and cleaning in Excel 
(Microsoft Office Excel 2013, Microsoft Corp.). The sex and 
neuter status, coat colour, breed and age of the cat when the 
hydrolysed diet was first prescribed were described.
Analyses were performed using a computer software package 
(IBM SPSS Statistics Version 26). Univariable and multivariable 
binary logistic regression modelling was used to assess the follow-
ing variables for associations with the odds of a poor response: 
(1) age when the hydrolysed diet was first prescribed, (2) coat 
colour, (3) sex and neuter status, (4) breed, (5) pre-treatment 
subcategory; consisting of whether antibiotic and/or glucocor-
ticoid had been prescribed for vomiting/diarrhoea at any visit 
before the hydrolysed diet being first prescribed and (6) treat-
ment subcategory; consisting of whether antibiotic and/or glu-
cocorticoid had been prescribed concurrently with the diet when 
first prescribed. Age was categorised as equal/less than 6 years or 
greater than 6 years based on the median cut-off of age for all 
cats. Coat colour and breed were categorised into 11 categories 
each, as depicted in Table  3. Sex and neuter status were cate-
gorised as male entire, male neutered, female entire and female 
neutered. Pre-treatment subcategory was categorised as (1) no 
antibiotic or glucocorticoid prescribed for vomiting/diarrhoea 
before the diet, (2) antibiotic but no glucocorticoid prescribed 
for vomiting/diarrhoea before the diet, (3) glucocorticoid but no 
antibiotic prescribed for vomiting/diarrhoea before the diet and 
(4) both antibiotic and glucocorticoid prescribed for vomiting/
diarrhoea before the diet. Treatment subcategory was categorised 
as (1) hydrolysed diet without concurrent antibiotic or glucocor-
ticoid, (2) hydrolysed diet with concurrent antibiotic (without 
glucocorticoid) and (3) hydrolysed diet with concurrent gluco-
corticoid (with or without antibiotic).
Variables associated with a poor response with a P-value <0.2 in 
the univariable analysis were taken forward into multivariable analy-
sis. Multivariable models were built using a backward stepwise elimi-
nation method. All promoted variables were initially included, and 
the variable with the highest P-value was removed until all remaining 
variables had a P-value <0.05. Potential confounders were assessed 
by checking the removed variables for a marked change in the OR 
after re-addition to the final model. Collinearity was investigated 
by examining the variance inflation factor (VIF) and tolerance of 
Table 1. Summarises the methodology used for determining the response in cats to a hydrolysed diet with or without 
concurrent antibiotic and/or glucocorticoid for chronic vomiting and/or diarrhoea of undetermined aetiology
Search terms for HA diet revealed 5569 cats out of 512,213 (1.1%)
5000 out of 5569 (90%) cats randomly selected and coded
Inclusion criteria Exclusion criteria
• First received HA diet for V ± D of at least 2 weeks duration
•  No concurrent conditions that might also be associated with receiving the HA diet (e.g. 
dermatological)
• Diet not refunded or discontinued within 1 month of dispensing
• Referral notes available if cases were referred for GI signs
• At least 6 months follow-up at same practice unless died or were euthanased due to GI signs
• Diagnostic investigations did not reveal an aetiology for the V ± D, other than CIE
•  Prior medical records unavailable if already 
receiving a HA diet for GI signs
•  GC started within a week of starting the diet for 
non-GI condition
977/5000 cats (19.5%) met criteria
Following extracted from medical records of all 977 cats:
1. VISITS BEFORE HA DIET: whether DW, AB or GC prescribed for V/D
2. VISIT WHEN HA DIET FIRST PRESCRIBED: whether AB or GC prescribed with diet:
A. No concurrent AB or GC
B. Concurrent AB (without GC)
C. Concurrent GC (±AB)
3. VISITS AFTER THE HA DIET (at least 6 months FU):
• For cats in Group A: if AB or GC prescribed for on-going V/D
• For cats in Group B: if more AB or GC prescribed for on-going V/D
• For cats in Group C: if more GC or AB prescribed for on-going V/D at least 3 months after first starting the diet
• For all cats:
• If non-GC anti-inflammatory/immunosuppressives prescribed for V/D
• If cat died or was euthanased for GI condition
• SEX/NEUTER STATUS, BREED, COAT COLOUR AND AGE WHEN HA DIET FIRST PRESCRIBED
Abbreviations: HA hydrolysed, V vomiting, D-diarrhoea, GI gastrointestinal, DW dewormer, AB antibiotic, GC glucocorticoid, CIE chronic inflammatory enteropathy, FU follow up.
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the variables taken forward to the multivariable analysis, with col-
linearity indicated if VIF > 10 and tolerance <0.1 (Myers  1990, 
Menard  1995). Pairwise interactions were assessed between the 
final variables that were significantly associated with poor response. 
Model fit was assessed using the Hosmer-Lemeshow Test and by cal-
culating the area under the receiver operating characteristic (ROC) 
curve (Hosmer & Lemeshow 2000).
RESULTS
Population summary of all cats
The study population included 512,213 cats under primary vet-
erinary care at 876 veterinary clinics during 2016. The hydrolysed 
diet search terms found 5569 candidate cats of which a random 
subset of 5000 (90%) were randomly reviewed against the inclu-
FIG 1. Flow chart demonstrating exclusion criteria used for our study. Cats were excluded if they were not receiving a hydrolysed diet (for example 
medical records subsequently showed the cat to be consuming hypoallergenic treats, or “allergy” was flagged as a treatment but did not pertain to 
a hydrolysed diet) (n = 748) or received a hydrolysed diet for other reasons that did not include vomiting and/or diarrhoea (n = 2355). Cats were 
excluded if they first received the diet for less than 2 weeks of vomiting and/or diarrhoea (n = 130) or the time-line for these signs were not specified 
in the records (n = 83). Also, those cats that had concurrent dermatological signs and this was also a reason for prescribing the hydrolysed diet 
were excluded (n = 119). For those cats that had first received the diet for vomiting and/or diarrhoea of at least 2 weeks duration but had less than 
6 months of follow-up at the same practice, unless the cat died or was euthanased for GI signs were excluded (n = 183). Also, for those cats that 
were already receiving a hydrolysed diet for vomiting and/or diarrhoea at the time of first visit to the practice and therefore the duration, diagnostic 
investigations and prior treatment of these signs were unavailable for review were excluded (n = 120). Those cats that had been referred for the GI 
signs but the referral notes were unavailable for review were also excluded (n = 36). Additional exclusion criteria also included those cats that did 
not continue the diet, as the medical record showed that the diet had been refunded or specifically stated that the owners had stopped feeding the 
diet within 1 month of it being prescribed (n = 118) and if diagnostic investigations revealed an aetiology for the vomiting and/or diarrhoea that was 
not chronic inflammatory enteropathy (n = 128). Finally, three cats were excluded as they were prescribed glucocorticoids for non-gastrointestinal 
conditions (eosinophilic granuloma complex, regenerative anaemia and possible asthma) within 1 week of starting the diet. Abbreviations: Derm 
dermatology, FU follow-up, GC glucocorticoid, GI gastrointestinal, CIE chronic inflammatory enteropathy
Table 2. The number and percentages of poor response in cats prescribed a hydrolysed diet with or without concurrent 
antibiotic and/or glucocorticoid for chronic vomiting and/or diarrhoea of undetermined aetiology
Concurrent treatment when 
hydrolysed diet first prescribed
Definition of poor response Number (percentage) 
with poor response
Median follow-up time 
(range)
No antibiotic nor glucocorticoid 
(n = 697)
Received intervention with antibiotic or glucocorticoid for 
vomiting/diarrhoea at subsequent visits after the diet 
was first prescribed or death from GI signs
240 cats (34%) 818 days (184–3809)
Antibiotic (without glucocorticoid) 
(n = 127)
Received intervention with additional antibiotic or 
glucocorticoid for vomiting/diarrhoea at subsequent visits 
after the diet was first prescribed or death from GI signs
71 cats (56%) 946 days (186–3599)
Glucocorticoid (with or without 
antibiotic) (n = 153)
Received intervention with further glucocorticoid or 
antibiotic for vomiting/diarrhoea at least 3 months after 
the diet was first prescribed or death from GI signs
100 cats (65%) 1082 days (213–3888)
Hydrolysed diets in cats with vomiting/diarrhoea
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sion and exclusion criteria. A total of 977 of 5000 (19.5%) can-
didate cats met the case definition and inclusion criteria and were 
included in further analyses (Fig. 1). All 977 cats presented with 
chronic vomiting and/or diarrhoea of undetermined aetiology, of 
which 107 had inflammatory changes documented on intestinal 
histopathology.
The following diagnostic investigations were performed for the 
cats in our study: feline leukaemia and feline immunodeficiency 
virus testing in 127 (13%) cats, haematology and serum biochem-
istry in 704 (72%) cats, serum thyroxine concentration in 292 
(30%) cats, faecal analysis (faecal parasitology, ±faecal culture, 
±Giardia enzyme linked immunosorbant assay ±Tritrichomonas 
foetus polymerase chain reaction) in 424 (43%) cats, empirical 
deworming for GI signs in 457 (47%) cats, serum vitamin B12 
and folate in 325 (33%) cats, pancreatic lipase immunoreactivity 
in 347 (36%) cats, trypsin like immunoreactivity in 218 (22%) 
cats, trans-abdominal ultrasound in 349 (36%) cats and intesti-
nal histopathology in 123 (13%) cats, although for 16 cases, the 
results were not reported or reported as normal/unremarkable.
The median age of the 977 cats at the time the hydrolysed 
diet was first prescribed was 6.3 years  (Interquartile range (IQR) 
3.1-10.40, range  0.5-19.9). The most common breeds seen were: 
domestic shorthair (568, 58%), domestic longhair (87, 8.9%), 
British shorthair (52, 5.3%), Ragdoll (38, 3.9%), Persian (29, 
3.0%) and Maine coon (22, 2.3%) (Table 3). The most com-
mon coat colours were: black and white (161, 16.5%), black 
(128, 13.1%), tabby (119, 12.2%), tortoiseshell (65, 6.7%), gin-
ger (47, 4.8%) and blue (44, 4.5%) (Table 3). There were 107 
(11%) entire females, 94 (9.6%) entire males, 333 (34%) neu-
tered females, 440 (45%) neutered males and 3 (0.3%) unknown 
sex and neuter status.
Four hundred and ninety nine (51%) and 164 (17%) cats 
were prescribed antibiotic and glucocorticoid, respectively for 
vomiting/diarrhoea at visits before the hydrolysed diet was first 
prescribed, while 435 (45%) had no evidence of prior treatment 
with either therapy before dietary prescription.
Cats first prescribed the diet without concurrent 
antibiotic and glucocorticoid
Of the 697 cats (71% of all), first prescribed the hydrolysed diet 
without concurrent antibiotic and glucocorticoid, 457 (66%) did 
not have a poor response for a median follow-up time of 818 days 
(range 184-3809) (Table 2). Of the remaining 240 (34%) cats 
that had a poor response, 5 were euthanased or died due to GI 
Table 3. Univariable logistic regression analyses results for associations with the odds of a poor response in cats that were 
prescribed a hydrolysed diet with or without concurrent antibiotic and/or glucocorticoid for chronic vomiting and/or diarrhoea
Variable Poor response N (%) Good response N (%) Odds ratio (95% 
confidence interval)
P-value
6 years of age 
and younger
Yes 153 (16.6%) 292 (31.7%) – –
No 227 (24.7%) 248 (27.0%) 1.75 (1.34–2.28) <0.001
Sex and neuter 
status
Male entire 33 (3.4%) 61 (6.3%) – –
Male neutered 194 (19.9%) 246 (25.3%) 1.46 (0.92–2.32) 0.111
Female entire 54 (5.5%) 55 (5.6%) 1.82 (1.03–3.20) 0.039
Female neutered 129 (13.2%) 202 (20.7%) 1.18 (0.73–1.90) 0.500
Coat colour Black and white 65 (6.7%) 91 (9.3%) – –
Black 46 (4.7%) 81 (8.3%) 0.80 (0.49–1.29) 0.351
Tabby 44 (4.5%) 75 (7.7%) 0.82 (0.50–1.34) 0.431
Tortoiseshell 26 (2.7%) 39 (4.0%) 0.93 (0.52–1.68) 0.819
Ginger 18 (1.8%) 29 (3.0%) 0.87 (0.45–1.70) 0.681
Blue 23 (2.4%) 21 (2.1%) 1.53 (0.78–3.00) 0.212
Ginger and white 17 (1.7%) 22 (2.3%) 1.08 (0.53–2.20) 0.828
Tabby and white 11 (1.1%) 27 (2.8%) 0.57 (0.26–1.23) 0.153
White 13 (1.3%) 14 (1.4%) 1.30 (0.57–2.95) 0.530
White and grey 11 (1.1%) 15 (1.5%) 1.03 (0.44–2.38) 0.951
Combination of all remaining coat 
colours
137 (14%) 152 (15.6%) 1.26 (0.85–1.87) 0.246
Breed Domestic shorthair 221 (22.6%) 347 (35.5%) – –
Domestic longhair 35 (3.6%) 52 (5.3%) 1.06 (0.67–1.68) 0.814
British short hair 24 (2.5%) 28 (2.9%) 1.35 (0.76–2.38) 0.308
Ragdoll 17 (1.7%) 21 (2.1%) 1.27 (0.66–2.46) 0.477
Persian 13 (1.3%) 16 (1.6%) 1.28 (0.60–2.70) 0.525
Maine coon 14 (1.4%) 8 (0.8%) 2.75 (1.13–6.66) 0.025
Bengal 10 (1.0%) 9 (0.9%) 1.75 (0.70–4.36) 0.234
Burmese 9 (0.9%) 5 (0.5%) 2.83 (0.94–8.54) 0.066
Birman 6 (0.6%) 5 (0.5%) 1.88 (0.57–6.25) 0.300
Domestic medium hair 3 (0.3%) 7 (0.7%) 0.67 (0.17–2.63) 0.569
Combination of all remaining breeds 59 (6.0%) 68 (7.0%) 1.36 (0.93–2.01) 0.118
Pre-treatment 
subcategory
No AB or GC 139 (14.2%) 296 (30.0%) – –
AB but no GC 168 (17.2%) 210 (21.5%) 1.70 (1.28–2.27) <0.001
GC but no AB 30 (3.1%) 13 (1.3%) 4.91 (2.49–9.71) <0.001
AB and GC 74 (7.6%) 47 (4.8%) 3.35 (2.21–5.09) <0.001
Treatment 
subcategory
No concurrent AB or GC 240 (24.6%) 457 (46.8%) – –
Concurrent AB (without GC) 71 (7.3%) 56 (5.7%) 2.41 1(1.65–3.54) <0.001
Concurrent GC (with or without AB) 100 (10.2%) 53 (5.4%) 3.59 (2.49–5.19) <0.001
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signs at a subsequent visit without receiving antibiotic or gluco-
corticoid for their vomiting/diarrhoea, 76 were prescribed anti-
biotic for vomiting/diarrhoea at a subsequent visit; 1 of which 
was ultimately euthanased for GI signs and 159 were prescribed 
glucocorticoid with or without antibiotic for vomiting/diarrhoea 
at subsequent visits, of which 38 of these ultimately died or were 
euthanased for GI signs. Of these 240 cats with a poor response, 
18 also received other non-glucocorticoid anti-inflammatory or 
immunosuppressive medication at subsequent visits for vomit-
ing/diarrhoea. Two cats received sulfasalazine, 5 cats cyclospo-
rine, 8 cats chlorambucil, 2 cats chlorambucil and cyclosporine 
and 1 cat chlorambucil and sulfasalazine. Of these 18 cats, 6 died 
or were euthanased for GI signs at a subsequent visit.
Cats first prescribed the diet with concurrent 
antibiotic (without glucocorticoid)
Of the 127 cats (13% of total) first prescribed the diet with con-
current antibiotic (without glucocorticoid), 56 (44%) did not 
have a poor response for a median follow-up time of 946 days 
(range 186-3599) (Table 2). Of the remaining 71 cats (56%) 
that had a poor response, 34 were prescribed further antibi-
otic for vomiting/diarrhoea at a subsequent visit; 3 of which 
were ultimately euthanased for GI signs and 37 were prescribed 
glucocorticoid with or without antibiotic for vomiting/diar-
rhoea at subsequent visits, of which 8 ultimately died or were 
euthanased for GI signs. Of these 71 cats, 5 also received other 
non-glucocorticoid anti-inflammatory or immunosuppressive 
medication at subsequent visits for vomiting/diarrhoea. One 
cat received cyclosporine, 3 cats chlorambucil and 1 cat sul-
fasalazine. Of these 5 cats, 1 was euthanased for GI signs at a 
subsequent visit.
Cats first prescribed the diet with concurrent 
glucocorticoid (with or without antibiotic)
In the 153 cats (16% of total) that were first prescribed the diet 
with concurrent glucocorticoid (with or without antibiotic), 
53 cats (35%) did not have a poor response for a median fol-
low-up time of 1082 days (range 213-3888) (Table 2). Of the 
remaining 100 cats (65%) that had a poor response, 16 were 
euthanased or died due to vomiting/diarrhoea at a subsequent 
visit within 3 months of first receiving the hydrolysed diet and 
concurrent glucocorticoid. Eighty-four cats continued to receive 
glucocorticoid or were prescribed antibiotic or glucocorticoid 
for  vomiting/diarrhoea at subsequent visits at least 3 months 
after first receiving the hydrolysed diet and concurrent gluco-
corticoid; 18 of which ultimately died or were euthanased for 
GI signs. Of these 100 cats, 8 also received other non-gluco-
corticoid anti-inflammatory or immunosuppressive medication 
at subsequent visits for vomiting/diarrhoea. Two cats received 
cyclosporine, 5 cats chlorambucil and 1 cat both cyclosporine 
and chlorambucil. Of these 8 cats, 4 were euthanased for GI 
signs at a subsequent visit.
Univariable and multivariable analysis of poor 
response for all cats
There were four variables that were liberally significant in uni-
variable analysis and were promoted for multivariable analysis: 
the age of the cat when the hydrolysed diet was first prescribed, 
sex and neuter status, pre-treatment subcategory and treatment 
subcategory (Table  3). After accounting for the other factors, 
the final multivariable model showed that cats aged over 6 years 
when first prescribed the diet had increased odds of a poor 
response compared to cats that were 6 years of age and younger 
(OR 1.81, 95% CI: 1.37-2.40, P < 0.001) (Table 4). For the pre-
treatment subcategory, cats that were prescribed antibiotic and 
cats that were prescribed glucocorticoids before the hydrolysed 
diet had increased odds of a poor response compared to those 
cats that received no antibiotic or glucocorticoid before the diet 
(OR 1.55, 95% CI: 1.14-2.11, P = 0.005 and OR 4.11, 95% CI: 
2.00-8.43, P < 0.001, respectively) (Table 4). Cats that were pre-
scribed both antibiotic and glucocorticoid before the hydrolysed 
diet had 2.42 times the odds (95% CI: 1.51-3.86, P < 0.001) of 
a poor response compared to those cats that received no antibi-
otic or glucocorticoid before the diet. In relation to the treat-
ment subcategory, cats that were first prescribed the diet with 
concurrent antibiotic or glucocorticoid had increased odds of a 
poor response compared to those cats that received no antibiotic 
or glucocorticoid when the diet was first prescribed (OR 2.08, 
95% CI: 1.38-3.11, P < 0.001 and OR 2.66 95% CI: 1.76-4.00, 
P < 0.001, respectively) (Table  4). Sex and neuter status, coat 
colour and breed were not associated with the odds of a poor 
response. Pairwise interaction showed no significant associations 
between the three variables in the final model. The Hosmer-
Lemeshow test indicated good model fit (P = 0.812), and the 
area under ROC curve (0.679) indicated moderate predictive 
ability.
Table 4. Multivariable logistic regression analyses results for associations with the odds of a poor response in cats that were 
prescribed a hydrolysed diet with or without concurrent antibiotic and/or glucocorticoid for chronic vomiting and/or diarrhoea
Variable Poor response N (%) Good response N (%) Odds ratio (95% 
confidence interval)
P-value
6 years of age and 
younger
Yes 153 (16.6%) 292 (31.7%) – –
No 227 (24.7%) 248 (27.0%) 1.81 (1.37–2.40) <0.001
Pre-treatment 
subcategory
No AB or GC 139 (14.2%) 296 (30.0%) – –
AB but no GC 168 (17.2%) 210 (21.5%) 1.55 (1.14–2.11) 0.005
GC but no AB 30 (3.1%) 13 (1.3%) 4.11 (2.00–8.43) <0.001
AB and GC 74 (7.6%) 47 (4.8%) 2.42 (1.51–3.86) <0.001
Treatment 
subcategory
No concurrent AB or GC 240 (24.6%) 457 (46.8%) – –
Concurrent AB (without GC) 71 (7.3%) 56 (5.7%) 2.08 (1.38–3.11) <0.001
Concurrent GC (with or without AB) 100 (10.2%) 53 (5.4%) 2.66 (1.76–4.00) <0.001
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DISCUSSION
This is the first study to describe response to commercial hydro-
lysed diets in cats with chronic vomiting and/or diarrhoea of 
undetermined aetiology under primary veterinary care. Overall 
in our study, 42% of cats that were first prescribed a hydrolysed 
diet with or without concurrent antibiotic and/or glucocorticoid 
had a poor response, as evidenced by further prescription of anti-
biotic and/or glucocorticoid therapy or death associated with 
the GI condition, for a minimum follow-up period of 6 months. 
Antibiotic and/or glucocorticoid administration before and con-
current with the diet were associated with higher odds of a poor 
response, although our study was unable to determine the cau-
sality behind this association. Possible explanations include the 
association of antibiotic and glucocorticoid usage with severity of 
GI signs, prescribing habits of primary care veterinary surgeons, 
for example clinicians more likely to use these medications before 
the diet are more likely to use them after the diet for episodes of 
vomiting/diarrhoea or, the effects of antibiotic and glucocorti-
coid on the intestinal microbiota and mucosal immune system, 
respectively reducing the effectiveness of a hydrolysed diet.
The treatment plan for suspected or confirmed CE often follows 
a sequential or combination approach with diet, antibiotics and 
glucocorticoids depending on the severity of signs (Jergens 2012). 
Therefore, antibiotic and glucocorticoid are likely to be used 
before, concurrently or subsequent to dietary intervention for those 
cases with more severe clinical signs. Studies have demonstrated 
that clinical disease activity scores are negatively correlated with 
treatment response and outcome in dogs (Allenspach et al. 2007, 
Kathrani et al.  2019) and the same is likely true for feline CE. 
Therefore, cats first prescribed a hydrolysed diet with concurrent 
antibiotic and/or glucocorticoid might be more severely clinically 
affected before therapy and therefore more likely to have a poor 
response. Further studies are needed to confirm the relative con-
tributions from clinical disease severity and the use of concurrent 
antibiotic and/or glucocorticoid to the odds of a poor response.
Hypocobalaminaemia has also been shown to be a negative 
prognostic indicator in dogs with CE and may predict refractori-
ness to treatment (Allenspach et al. 2007). In cats, hypocobala-
minaemia has been shown to be a negative prognostic indicator 
in alimentary lymphoma (Kiselow et al.  2008). In addition, 
cobalamin supplementation in cats with small intestinal disease 
and severe hypocobalaminaemia can help to improve clinical 
signs in most affected cats (Ruaux et al. 2005). Hypocobalami-
naemia may also be associated with refractoriness to treatment in 
cats with CE (Jergens 2012). Although, in our study only a third 
of cats had serum cobalamin concentration measured, unfortu-
nately we did not take into consideration the serum cobalamin 
concentration of these cats or the effect of additional supplemen-
tation on treatment response. Therefore, future studies will aim 
to determine the clinicopathological variables that help to predict 
treatment response to hydrolysed diets and the effects of concur-
rent cobalamin supplementation on this response in these cats. 
This will then help to confirm the relative contributions from 
hypocobalaminaemia and the use of prior or concurrent antibi-
otic and/or glucocorticoid to the odds of a poor response.
The majority of cats in our study were treated for suspected 
CE rather than definitive CE. Therefore, the cats first prescribed 
a hydrolysed diet with concurrent antibiotic and/or glucocor-
ticoid may have had more severe clinical signs due to alimen-
tary neoplasia rather than CE and therefore inherently a poorer 
response to treatment. Unfortunately, restricting our study to 
those cats that were definitively diagnosed with CE following 
intestinal histopathology would have eliminated almost 90% 
of the cats and would not have accurately reflected the overall 
population that commonly present to primary practices where 
these diets are empirically used before intestinal biopsy. In addi-
tion, to ensure our results were relevant to the majority of cats 
that are empirically treated with these diets in primary veterinary 
practice, there were no minimum required diagnostic tests for 
inclusion. However, further studies using defined population of 
cats with chronic vomiting and/or diarrhoea with standardised 
investigations performed, such as a minimum of retroviral test-
ing, haematology, serum biochemistry, serum thyroxine for cats 
>6 years of age and faecal analysis or empirical deworming for 
cats with diarrhoea and ideally trans-abdominal ultrasound and 
further laboratory tests such as serum vitamin B12, folate, tryp-
sin like immunoreactivity and pancreatic lipase immunoreactiv-
ity will help to inform primary care veterinary surgeons about 
cats that are the best candidates for treatment with these diets. 
Furthermore, defining the population of cats according to spe-
cific GI signs, such as vomiting alone or predominantly large 
intestinal diarrhoea will also help inform primary care veterinary 
surgeons about which specific GI signs may benefit from treat-
ment with these diets.
Although the majority (71%) of the cats in our study were 
first prescribed a hydrolysed diet without concurrent antibiotic 
or glucocorticoid, these medications had been used for vomit-
ing and/or diarrhoea before the initiation of the diet in over 
50% of cases. In our study, the use of these medications before 
the use of the diet was associated with higher odds of a poor 
response. Although, this might have been due to the prescrib-
ing habits of primary care veterinary surgeons, for example cli-
nicians more likely to use these medications before the diet are 
more likely to use them after the diet for vomiting/diarrhoea 
compared to those that did not use these medications before the 
diet. Another explanation for this finding includes the potential 
negative effect of antibiotics on the intestinal microbiota (Man-
chester et al.  2019). The possible resultant intestinal dysbiosis 
that may arise from the antibiotic may then subsequently affect 
the response to a hydrolysed diet. Similarly, glucocorticoids have 
an effect on the mucosal immune system by dampening inflam-
mation (Coutinho & Chapman 2011), which may also subse-
quently affect the response to a hydrolysed diet. Further studies 
utilising randomised controlled trials rather than observational 
studies are needed to determine whether antibiotic or glucocorti-
coid use before a hydrolysed diet affects the outcome. Also, fur-
ther studies are needed to support or refute the use of antibiotics 
in cats with chronic GI signs of undermined aetiology, due to the 
concerns regarding intestinal dysbiosis and antibiotic resistance 
with their use. Therefore, empirical use of antibiotics before, 
during or after multiple failed dietary trials utilising different 
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strategies should be cautioned against until more evidence for 
their efficacy is available in cats with chronic GI signs of unde-
termined aetiology.
For those cats that were first prescribed diet without con-
current antibiotic or glucocorticoid, only 34% showed a poor 
response. This is similar to canine studies assessing the effect 
of diet alone on CE or chronic GI signs (Craven et al.  2004, 
Allenspach et al. 2007, 2016, Volkmann et al. 2017). Similarly, 
when using a commercial hydrolysed diet, 66.6% of dogs with 
CE were categorised as food-responsive (Marks et al.  2002, 
Mandigers et al.  2010b). Unfortunately, our study is unable 
to report on the effectiveness of hydrolysed diets in cats with 
chronic vomiting and/or diarrhoea, as a control group of cats 
not receiving these diets was not included. Comparison to a 
control group of cats receiving a non-hydrolysed diet is impor-
tant, as elimination of any causative dietary trigger in suscep-
tible cats by transitioning to a different diet, whether hydrolysed 
or not may be enough to resolve the clinical signs. Therefore, 
future studies assessing the effects of specific dietary strategies 
in cats with chronic GI signs should include a control group 
and should also take the full dietary history of each cat into 
consideration to determine the likelihood of a dietary trigger 
causing the chronic GI signs. Furthermore, unlike the canine 
studies above, our study did not assess reduction in clinical signs 
or disease activity score following initiation of treatment. The 
reason for not assessing clinical response in our study was this 
measure was deemed as subjective and not a measure that could 
be consistently assessed from all clinical records, especially as 
the cat may not have returned to the practice if their signs had 
improved or completely resolved. Therefore, in order to ensure 
the outcome measure was more objective and reliably assessed 
from all clinical records, subsequent prescription of antibiotic 
and/or glucocorticoid for on-going vomiting/diarrhoea at visits 
after the diet was prescribed was chosen. Further, our study does 
provide a benchmark for the number of cats returning with GI 
signs receiving treatment with antibiotic and/or glucocorticoid 
after initiation of hydrolysed diet in cats in primary practice. 
This will allow comparisons with other treatments, such as anti-
biotic alone, glucocorticoid alone, probiotic or other dietary 
strategies known to be effective for chronic idiopathic GI signs 
in cats, such as commercial therapeutic GI, limited-ingredient 
novel protein, modified fibre or low carbohydrate diets. This 
will then assist with decision-making on the best dietary strategy 
for these cases or define which cats are most likely to benefit 
from each of these diets, especially as dietary management of 
these cases currently involves trial and error to determine the 
best strategy for the individual patient.
Our study showed that cats above the age of 6 years had sig-
nificantly higher odds of poor response compared to cats 6 years 
of age and younger. A previous study in dogs showed that food-
responsive enteropathy cases were significantly younger compared 
to those dogs with CE that were treated with glucocorticoids in 
addition to diet (Allenspach et al. 2007). Another study, specifi-
cally in cats demonstrated that those with food-responsive enter-
opathy were younger (Gianella et al. 2017). Although, our study 
showed the same, another reason for this finding may be that 
older cats included in our study were more likely to have pre-
sented with undiagnosed conditions including alimentary neo-
plasia compared to the younger cats and therefore would be more 
likely to have a poor response to diet with or without concurrent 
antibiotic and/or glucocorticoid.
Our study had the additional following limitations: data 
entry was primarily recorded for clinical use and not for research 
purposes and may have therefore included some errors. Cats 
with concurrent dermatological signs at the time the diet was 
prescribed were excluded because these cats may have received 
dietary and/or medical therapy primarily for these signs rather 
than for the GI disease. Therefore, our study did not assess those 
cats with concurrent GI and dermatological signs that may have 
been food-responsive. Our study included only those cats that 
had diarrhoea, vomiting or both. Therefore cats with GI disease 
that had clinical signs recorded solely as weight loss or hyporexia 
were excluded. Our study did not take into account the dose and 
duration of medications or severity of clinical signs, which may 
have all contributed to treatment response. Our study assumed 
that diets that were not returned were fed, especially in light of 
the manufacturers money-refund guarantee with therapeutic 
diets. The indoor/outside status of the cat and access to addi-
tional foods was not taken into consideration. However, a recent 
study suggested that dogs with food-responsive enteropathy did 
not need to receive these diets exclusively for effectiveness at 
controlling clinical signs (Allenspach et al.  2016). Also, as the 
medical records for each cat only goes as far back as their first 
presentation to that practice, the use of antibiotic or glucocorti-
coid for vomiting/diarrhoea before this first visit can not be com-
pletely excluded in those cats that were reported not to receive 
these medications before initiation of the diet. However, cases 
that mentioned prior GI signs or treatment at previous prac-
tices when the GI signs were first described in the record were 
excluded if their prior notes were unavailable for review. Finally, 
data were reviewed and extracted by a single operator, which may 
have resulted in more errors than if two independent operators 
had performed data extraction (Buscemi et al. 2006). Therefore, 
future similar studies will aim to include two independent opera-
tors for data review and extraction.
In conclusion, 42% of cats prescribed a hydrolysed diet with or 
without concurrent antibiotic and/or glucocorticoid for chronic 
vomiting and/or diarrhoea of undetermined aetiology had a poor 
response for a follow-up period of at least 6 months. Cats that 
received antibiotic and/or glucocorticoid before or concurrently 
with the diet had higher odds of a poor response. However, fur-
ther studies utilising randomised controlled trials rather than 
observational studies are needed to determine whether antibiotic 
or glucocorticoid use before or concurrently with a hydrolysed 
diet affects the outcome. Nevertheless, our results suggest that 
there is merit in trialling a hydrolysed diet first as a sole therapy 
in cats with chronic vomiting and/or diarrhoea of undetermined 
aetiology before resorting to antibiotic and/or glucocorticoid 
therapy for cases that respond poorly.
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